These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 14703954)

  • 21. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation.
    International Neoral Renal Transplantation Study Group.
    Am J Transplant; 2002 Feb; 2(2):148-56. PubMed ID: 12099517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of cyclosporine A in rat tissues and human kidney transplant biopsies--a method suitable for small (<1 mg) samples.
    Noll BD; Coller JK; Somogyi AA; Morris RG; Russ GR; Hesselink DA; van Gelder T; Sallustio BC
    Ther Drug Monit; 2011 Dec; 33(6):688-93. PubMed ID: 22105584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis.
    Wang CE; Lu KP; Chang Z; Guo ML; Qiao HL
    Gene; 2018 Jul; 664():44-49. PubMed ID: 29678659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients.
    Frassetto LA; Tan-Tam CC; Barin B; Browne M; Wolfe AR; Stock PG; Roland M; Benet LZ
    Transplantation; 2014 Mar; 97(6):702-7. PubMed ID: 24389906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
    Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclosporine C2 levels in de novo renal allograft recipients: a German multicenter prospective observational study.
    Arns W; Zantvoort F; Abendroth D; Seiter H; Scheuermann EH; Albert U; Stahl R; Fornara P; Fricke L; Neumayer HH; Nagel E; Michel U; Ulbricht B
    Transplant Proc; 2005 Apr; 37(3):1612-5. PubMed ID: 15866687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation.
    Keown PA; Kiberd B; Balshaw R; Khorasheh S; Marra C; Belitsky P; Kalo Z
    Pharmacoeconomics; 2004; 22(10):621-32. PubMed ID: 15244488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation.
    Mahalati K; Belitsky P; Sketris I; West K; Panek R
    Transplantation; 1999 Jul; 68(1):55-62. PubMed ID: 10428267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption.
    Trompeter R; Fitzpatrick M; Hutchinson C; Johnston A
    Pediatr Transplant; 2003 Aug; 7(4):282-8. PubMed ID: 12890006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of C0 and C2 cyclosporine monitoring in long-term renal transplant recipients.
    Marcén R; Pascual J; Tato A; Villafruela JJ; Teruel JL; Rivera ME; Tenorio M; Fernández M; Burgos FJ; Ortuño J
    Transplant Proc; 2003 Aug; 35(5):1780-2. PubMed ID: 12962793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection.
    Kahan BD; Welsh M; Schoenberg L; Rutzky LP; Katz SM; Urbauer DL; Van Buren CT
    Transplantation; 1996 Sep; 62(5):599-606. PubMed ID: 8830822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.
    Loichot C; Bentue-Ferrer D; Bernard N; Bonardet A; Boulieu R; Kergueris MF; Paintaud G; Peytavin G; Simon N; Marquet P;
    Fundam Clin Pharmacol; 2006 Feb; 20(1):91-6. PubMed ID: 16448399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients.
    Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R
    Pediatr Transplant; 1999 Nov; 3(4):282-7. PubMed ID: 10562972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale for monitoring cyclosporine concentration at 2 hours after administration in infants posttransplantation.
    Furlan V; Lykavieris P; Maubert MA; Habes D; Debray D
    Transplant Proc; 2009 Oct; 41(8):3333-4. PubMed ID: 19857744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F; Marti HP; Frey FJ; Uehlinger DE
    Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic drug monitoring of cyclosporine.
    Midtvedt K
    Transplant Proc; 2004 Mar; 36(2 Suppl):430S-433S. PubMed ID: 15041380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical experience with everolimus (Certican) in young renal transplant recipients.
    Eris J
    Transplantation; 2005 May; 79(9 Suppl):S89-92. PubMed ID: 15880023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.